Increased pretreatment levels of serum LDH and ALP as poor prognostic factors for nasopharyngeal carcinoma

Nasopharyngeal carcinoma (NPC) is a type of cancer that originates in the nasopharynx, which is the upper part of the throat behind the nose. It is a rare cancer in most parts of the world but is more common in certain regions, such as Southeast Asia, North Africa, and the Middle East.

There are several factors that can affect the prognosis of NPC, including the stage of the cancer, the age and overall health of the patient, and the levels of certain biomarkers in the blood. Two such biomarkers are serum lactate dehydrogenase (LDH) and alkaline phosphatase (ALP).

LDH is an enzyme that is found in many tissues throughout the body, including the liver, heart, and muscles. When cells are damaged, LDH is released into the bloodstream, leading to increased levels in the blood. ALP is an enzyme that is primarily found in the liver and bones, and increased levels in the blood can indicate liver or bone damage.

Several studies have shown that increased pretreatment levels of LDH and ALP are associated with poorer prognosis for patients with NPC. For example, a study published in the journal Cancer Science in 2015 found that patients with high pretreatment levels of LDH had significantly lower overall survival rates than those with low levels. Similarly, a study published in the Journal of Cancer in 2016 found that high pretreatment levels of ALP were associated with a higher risk of distant metastasis and poorer overall survival.

Overall, these findings suggest that pretreatment levels of LDH and ALP can be useful biomarkers for predicting the prognosis of NPC. Patients with high levels of these biomarkers may require more aggressive treatment and closer monitoring to improve their outcomes